Rewinding the biological clock

Here at Maclean's, we appreciate the written word. And we appreciate you, the reader. We are always looking for ways to create a better user experience for you and wanted to try out a new functionality that provides you with a reading experience in which the words and fonts take centre stage. We believe you'll appreciate the clean, white layout as you read our feature articles. But we don't want to force it on you and it's completely optional. Click "View in Clean Reading Mode" on any article if you want to try it out. Once there, you can click "Go back to regular view" at the top or bottom of the article to return to the regular layout.

Francis Leroy / Biocosmos / Science Photo Library

Reproductive biologists have been working for decades to solve one of the great mysteries of human fertility: why do women produce all the eggs they will ever have while still in the womb, only to have most of those eggs die off before birth, and many more before the woman reaches puberty?

Jonathan Tilly, chair of the biology department at Northeastern University in Boston, was among those drawn to studying this enduring puzzle. But what he found instead was evidence of a fundamental flaw in the basic tenets that govern our understanding of the female reproductive system. If successful, his research could open the door to the most radical advancement in infertility treatment since in vitro fertilization was invented nearly 40 years ago.

When Tilly examined the ovaries of mice, he noticed that their eggs were dying much faster than the overall egg count would suggest. The mice appeared to be producing new eggs, and were doing so by a process that no one really understood.

Tillys team began researching the role that stem cells play in the process. Chinese researchers later identified a specific type of stem cell located in the ovarian tissue.

Last year, Tillys team published evidence that the same process happening in mice was occurring in humans. He isolated human ovarian stem cells and then implanted them into mice to produce an immature egg called an oocyte.

The implications are huge. If a woman continues to produce eggs into adulthood, then menopause doesnt happen because her body has exhausted its lifetime supply of eggs, but because the process to make new ones has stopped working. It also means that infertility problems in older women arent happening because the eggs she is born with have grown too old, but because the bodys quality-control process has broken down so that it is pumping out poor-quality new eggs.

Theres not a lot you can do about an egg that is 40 years old and has gone bad because of 40 years of accumulated damage, says Tilly. But there is something very much one can do if the egg quality really reflects not eggs going stale, but a production pipeline thats run amiss.

More importantly, if researchers could find a way to somehow kick-start the ovarian stem cells in older women who had stopped producing viable eggs, they could potentially rewind the biological clock.

See more here:
Rewinding the biological clock

INVESTOR INTEREST STRONG FOR STEM CELL COMPANIES

By Bradley J. Fikes U-T 12:01 a.m.Oct. 16, 2013

Good stem cell companies will get the funding they need to bring their products to market, financial and medical executives said at this years Stem Cell Meeting on the Mesa.

Biotech companies continue to attract investor interest, speakers said at the meeting this week in La Jolla, pointing to a stream of biotech initial public offerings as well as purchases of biotechs by large pharmaceutical companies.

However, theres a catch: Companies may get a lower value than they seek.

The field of stem cell therapies, also known as regenerative medicine, is making the transition from pure science to clinical medicine. San Diegos Cytori Therapeutics is testing a device to harvest a patients stem cells for treating heart diseases and repairing tissue defects. And in a much-watched trial, a cure for HIV infection is being tested by Sangamo BioSciences, based in Richmond.

The challenge for stem cell companies is to convince investors that their science is actually geared toward products that can be sold, said Ted Roth, president of Newport Beach-based Roth Capital Partners. Compared with 20 years ago, investors are much more sophisticated and arent dazzled by technology, he said.

How can you convince me this is not a science project? is the question these companies need to answer, Roth said.

Those that convince investors can do very well, Roth said, citing recent examples. Stemline Therapeutics, for example, held its IPO at $10 a share in January. At the close of trading on Monday, Stemline shares closed at $36.52. Stemline is developing treatments to eliminate cancer stem cells.

On a smaller scale, Roth Capital helped Carlsbad-based International Stem Cell Corp. raise $3 million this summer, Roth said. International Stem Cell is developing a Parkinsons treatment derived from parthenogenetic, or unfertilized, human egg cells.

Roth spoke at a Monday afternoon discussion on financing. His colleague on the panel, Karl Handelsman, concurred.

See the original post:
INVESTOR INTEREST STRONG FOR STEM CELL COMPANIES

Amy Wagers receives New York Stem Cell Foundation-Robertson Stem Cell Prize

Public release date: 15-Oct-2013 [ | E-mail | Share ]

Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation

NEW YORK, NY (October 15, 2013) The New York Stem Cell Foundation (NYSCF) announced today that Amy Wagers, PhD, Professor at Harvard University, will be the 2013 recipient of the NYSCF Robertson Stem Cell Prize, which has been awarded since 2011 for extraordinary achievements in translational stem cell research by a younger scientist.

Dr. Wagers is the Forst Family Professor of Stem Cell and Regenerative Biology at Harvard University and an Early Career Scientist of the Howard Hughes Medical Institute. At Harvard, she leads an independent research program that focuses on the regulation and therapeutic potential of blood and muscle stem cells.

"Dr. Wagers' groundbreaking research on the biology of blood and muscle forming stem cells has opened up an avenue for cures of degenerative diseases of the aged," said Susan L. Solomon, CEO and Co-founder of NYSCF. "Her work has the potential to impact treatment of diabetes, cancer, and muscular dystrophy among many other devastating conditions."

As the population ages, therapies that delay or reverse degenerative changes associated with age are increasingly important. To date, few interventions show promise, but exciting work from Dr. Wagers' lab has uncovered a role for blood-borne factors. Her discovery of a hormone, GDF11, that regulates aging through stem cell "rejuvenation" has the potential to provide transformative new therapies for aging and chronic degenerative diseases.

"I am delighted that the NYSCF-Robertson Prize, which honors the most important research conducted by a young stem cell scientist, will this year recognize Dr. Amy Wagers. Her path-breaking work in understanding blood-forming and muscle-forming stem cells is precisely the kind of translational science that the NYSCF-Robertson Prize was created to encourage," said Julian Robertson, whose foundation underwrites the $200,000 prize. The terms of the prize require that the $200,000 stipend be used, at the recipients' discretion, to further support their research.

The NYSCF Robertson Stem Cell Prize was presented to Dr. Wagers at a ceremony in New York City by Susan L. Solomon on October 15.

The jury that selected Dr. Wagers consisted of Fiona Watt, DPhil, from King's College London in the United Kingdom; Lorenz Studer, MD, Director of the Sloan-Kettering Center for Stem Cell Biology; Irving Weissman, MD, Director of the Institute for Stem Cell Biology and Regenerative Medicine at the Stanford School of Medicine; and inaugural recipient of the NYSCF Robertson Stem Cell Prize, Peter J. Coffey, DPhil, Co-Executive Director of Translation UC Santa Barbara's Center for Stem Cell Biology and Engineering and Director of the London Project to Cure Blindness, University College London.

Dr. Wagers' current work focuses on defining the factors and mechanisms that modulate the migration, expansion, and regenerative potential of aging stem cells. Her work on GDF11, a circulating hormone that declines with age in mice and humans, has shown that restoring "youthful" levels of GDF11 in mice produces a striking reversal of age-related disease in multiple systems, especially skeletal muscle.

Follow this link:
Amy Wagers receives New York Stem Cell Foundation-Robertson Stem Cell Prize

Stem cell businesses keep growing

Good stem cell companies will get the funding they need to bring their products to market, financial and medical executives said at this year's Stem Cell Meeting on the Mesa.

Biotech companies continue to attract investor interest, speakers said at the meeting this week in La Jolla, pointing to a stream of biotech initial public offerings as well as purchases of biotechs by large pharmaceutical companies.

However, there's a catch: Companies may get a lower value than they seek.

The field of stem cell therapies, also known as regenerative medicine, is making the transition from pure science to clinical medicine. San Diego's Cytori Therapeutics is testing a device to harvest a patient's stem cells for treating heart diseases and repairing tissue defects. And in a much-watched trial, a cure for HIV infection is being tested by Sangamo BioSciences, based in Richmond.

The challenge for stem cell companies is to convince investors that their science is actually geared toward products that can be sold, said Ted Roth, president of Newport Beach-based Roth Capital Partners. Compared with 20 years ago, investors are much more sophisticated and aren't dazzled by technology, he said.

"How can you convince me this is not a science project?" is the question these companies need to answer, Roth said.

Those that convince investors can do very well, Roth said, citing recent examples. Stemline Therapeutics, for example, held its IPO at $10 a share in January. At the close of trading on Monday, Stemline shares closed at $36.52. Stemline is developing treatments to eliminate cancer stem cells.

On a smaller scale, Roth Capital helped Carlsbad-based International Stem Cell Corp. raise $3 million this summer, Roth said. International Stem Cell is developing a treatment for Parkinson's derived from parthenogenetic, or unfertilized, human egg cells.

Roth spoke at a Monday afternoon discussion on financing regenerative medicine. His colleague on the panel, Karl Handelsman, concurred.

"If you can make a strong quality business case, you can always raise money," said Handelsman, founder of Codon Capital.

See more here:
Stem cell businesses keep growing

International Stem Cell Corporation Announces New Data From Parkinson's Disease Program

CARLSBAD, CA--(Marketwired - Oct 16, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies announced the latest results from its Parkinson's disease program at the American Neurological Association's 2013 Annual Meeting.

Neural stem cell (NSC) potentially provide therapeutic benefit through multiple mechanisms of action including migration to the site of injury, secretion of neurotrophic factors, immunomodulation, cell replacement, and finally recovery of the endogenous neurons. The new data obtained as part of ISCO's collaboration with the Sanford Burnham Medical Research Institute, includes:

According to ISCO's, Chief Scientific Officer Dr. R. Semechkin, "These results are important because they establish a solid foundation for the clinical use of neural stem cells for the treatment of Parkinson's diseases. This also potentially opens up a number of other neurological indications, for example Alzheimer's disease, with this cellular product."

About ISCO's Parkinson's disease program

ISCO's program uses human parthenogenetic neural stem cells (hPNSC), a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. The hPNSC are self-renewing multipotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (1) differentiate into dopaminergic neurons and (2) express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new and revolutionary opportunity for the treatment of Parkinson's disease, especially in cases where current dopamine-replacement approaches fail to adequately control the symptoms.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

Read the original here:
International Stem Cell Corporation Announces New Data From Parkinson's Disease Program

Beverly Hills Stem Cell Clinic Now Offering the Option of Avoiding Surgery with Outpatient Stem Cell Injections

Beverly Hills, CA (PRWEB) October 15, 2013

The leading stem cell clinic in the greater Los Angeles area, Beverly Hills Orthopedic Institute of Cellular Therapy, is now offering patients the opportunity to avoid surgery with outpatient stem cell therapy. The stem cell treatments are offered by a Double Board certified orthopedic doctor and maintain minimal risk when compared with that of surgical procedures. For more information and scheduling, call the stem cell clinic today at (424) 253-5577.

Numerous small research studies such as the one last year at Hospital for Special Surgery have showed the benefits of stem cell treatments and platelet rich plasma therapy for arthritis of the spine and extremity joints such as the shoulder, hip or need. In addition, stem cell injections are also showing excellent results for soft tissue injury such as tendinitis in the elbow, shoulder and Achilles. For example, when the patient has tendinitis or a tear of the Achilles or rotator cuff, stem cell treatments may be able to help prepare and regenerate the areas to avoid the need for surgery.

There are several stem cell therapy options available at the clinic which include bone marrow derived or amniotic derived stem cell injections, along with platelet rich plasma therapy. In certain instances, the Board Certified doctor may find it beneficial to combine the treatment options as well.

The Medical Director at Beverly Hills Orthopedic Institute for Cellular Therapy is Dr. Raj, who for years has been one of America's Top Orthopedists along with an ABC News medical correspondent and an expert consultant on WebMD. He practices in both Beverly Hills and Dubai, offering expert regenerative medicine treatments with years of experience in the field.

Conditions that are seeing excellent results from the stem cell treatments include degenerative and rheumatoid arthritis of the extremities and spine, tendinitis, bursitis, ligament injuries, fractures, and degenerative disc disease.

For those suffering with any of these conditions who would like to avoid surgery with a low risk, outpatient treatment call (424) 253-5577.

Read more:
Beverly Hills Stem Cell Clinic Now Offering the Option of Avoiding Surgery with Outpatient Stem Cell Injections

ADVOCACY MindaNOW: Villa Medica Revisited: I saw stem cell ‘harvest’

GERMANY (MindaNews/15 October) This is a follow up report on my last published article about our return trip to VILLA MEDICA in Edenkoben, Germany for our familys continuing search for ways to cure my wife Beths ailing kidneys by trying the unorthodox treatment using fresh stem cells. If you recall, we went for the first time last November 2012 resulting to her kidneys recovering a bit but still not within safe levels. Hence this2nd visit buoyed by the modest improvementalmost one year after the first injections.

Day 1, Monday wearrived with some Davao friends on the same flight from Manila on board ETIHAD AIRLINE after a 14-hour flight with a brief stopover at Abu Dhabi. It was cold and chilly but VILLA MEDICAs luxurious Mercedes Benz van (with a built- in wine bar to boot) made the one and a half hour land trip along Germanys famous auto-bahn highway a pleasurable zippassing through verdant green landscapes that were starting to turngoldendue to the onset of autumn.

We arrived at the Regenerative Clinic on time for a mid-morning breakfast andmet upwith the rest of the group mostly from Davao arriving from other airlines. They were there trying for the first time Fresh Stem Cell Therapy FCT except for Beth and another friend from Davao who were on their 2nd visit after an encouraging first round of treatment about a year earlier. Well, for those who have no serious health conditions but arehere for rejuvenation, anti-ageing or just plain well-being, a single FCT treatment will suffice. Unless of course one wants to get the optimum experience for good health in which case Villa Medica is the modern day Mecca of sorts, authorized and licensedby the German health authorities as a holistic, regenerative cellular therapy clinic nestled in ahideaway amidst vineyards andforests. Edenkoben is a quaint old pre-warGerman town with narrow streets and brick houses with a high-walled religious nunnery converted into a winery today.

After breakfast, all of us were immediately directed to proceed to the common Infusion room where a cocktail of Vitamin B12, glutathione, Vitamin C was introduced intravenous, to open up and prepare the body for the following days stem cell injections.

Day 2, Tuesday. It was about 10 oclock In the morning while waiting in our room for the doctors to come for the injections when my daughter KRISTEL suddenly called me to say that I was being invited by BOBBY CHIA, the Thai owner of VILLA MEDICA to come down at the laboratory area in the basement. It was at that timewhen the mother pregnant sheep was to be slaughtered and the stem cells extracted from the young unborn fetus and immediately injected to guests. Yes, I was waiting for this moment. I purposely requested Bobby earlier to allow meto see for myself how the stem cells were harvested. Within 2 hours from harvesting, the stem cells must be injected on the receiver for maximum effect. In that condition, the young fresh cells are potent and not prone to cause adverse effects or rejection by humans.

Iwas told that the basic underlying principle in the Villa Medica procedure isthe centuries old health maxim same heals same. Meaning kidneys of the donor heal kidneys (for renal problems); heart heals heart (for heart ailments); pancreas for diabetics ; brain for autism, Parkinsons; testicles for sex potency and so on and so forth. In simple laymans words, the donor cells are said to function as catalysts that when injected in the buttocks of a person,trigger the receivers own aging or sick cells to start reacting by producing young cells which set in motion the process of cell repair and rejuvenation.

Moreover, young unborn sheep fetus was used successfully over the years, since 1913, and Villa Medica had been pioneering this regenerative process some 50 years with about 100,000 clients so far. And still counting.

So when I got word that I would be welcome to see the harvesting, I rushed down with Kristel and met up with two Singaporeans. Bobbywas there waiting and gave us lab gowns, masks, caps and fitted our shoes with sterilized plastic covers. Bobby merely said, Jess, you said you wanted to see this. So go aheadsee for yourself.

I could only reply, Wow! I quickly donned the standard sterile garbs and prepositioned myself at the glass windows. In the next room from my observation post were eight masked technicians also garbed in blue-colored lab gowns. They were busy methodically slicing from a slaughtered baby sheep on the operating table I saw them gingerly slicing into thin and small pieces the different organs and flesh of the donor and classifying them into small glass containers. Bobby earlier warned me not to accidentally touch a button at the connecting door because the required conditions were such that a mere whiffof air from the outer chamber could mean infecting and aborting the on-going procedure. It was that stringent and extremely sterile as required by German health authorities. Even the breeding and raising of the donor herd that Villa Medica maintained had to comply with strict government regulations.

Although masked, I recognized one of them, a Filipino doctor whom I knew since our first visit November last year. Dr Andrew Morato had been with Villa Medica for years. He spoke fluent German. Last time I met him, I thought some full-blooded German was speaking until I caught a glimpse ofhis standard Bicolano features. Dr. Andoy, although now a German citizen, is proud of being Pinoy.

View original post here:
ADVOCACY MindaNOW: Villa Medica Revisited: I saw stem cell ‘harvest’

Boston-based researchers make new development in stem cell research

Stem cell research is surrounded by loaded controversy over the bioethical issues that itposes.

What many peopledont understand is that there are two different types of stem cells currentlybeing used for research:embryonic and adult.Adult stem cell use isnot the causefordiscussion, allowingresearch to continue with the hopes of changing the treatment of disease.

Researchers worldwide, whohave alreadydeveloped varioustherapies to treat leukemia, alsohope to treat cancer, Parkinsons disease and spinal cord injuriesone day. Now, Boston-based researchers have made the next development in stem cellstudies, whichwill reap exciting benefitsfor a large population ofpatients suffering from inflammatory diseases.

A group of researchers from Brigham and Womens Hospital, theHarvard Stem Cell Institute, Massachusetts Institute of Technologyand Massachusetts General Hospital have uncovered a wayforstem cellstoact as a drug factory at thesite of inflammation in the body, according to a study published Oct. 4 on EurekAlert.

Oren Levy,the head researcher, said he isoptimistic about the discoverys potential to treat diseases such as myocardialinfarction, multiple sclerosisand even certain types of cancer.

Its important not to create false hope, but we do see a lot of progress to be made,Levy said.

What did they do? Levy,with the help ofcollaborators Jeffrey Karp,WeianZhao,MehmetFatihYanikand Charles Lin,began the researchas a proof-of-concept studyto determine whether it was even possible for their hypothesis to work in a localized region ofthe body.

Oren Levy said he and Boston researchers discovered a new way for stem cells to act as tiny drug factories at sites of inflammation in the body. This discovery may soon aid in the treatment of various diseases, including myocardial infarction, multiple sclerosis and certain types of cancer. PHOTO COURTESY OF OREN LEVY.

Modified strands of mRNA were inserted into connective tissue stem cells called mesenchymal stem cells(MSC), which are a type of adult stem cells. Upon mRNA insertion, the cells producedan anti-inflammatory moleculeknown as interleukin-10.

These modified human stem cells were then injected into the bloodstream of a mouse that was experiencing inflammation in the ear. The cells targeted the site of inflammation and released theanti-inflammatoryinterleukin-10 molecule, which was ableto reduce the swelling.

The rest is here:
Boston-based researchers make new development in stem cell research